CD274 and non-small cell lung carcinoma: The Keynote 997 phase II trial presented at the American Society of Clinical Oncology (ASCO) meeting in 2021 evidenced that pembrolizumab and concurrent CRT and 14 cycles of consolidation Pembrolizumab present promising antitumor activity, with an overall response rate (ORR) of 70%, regardless of PDL1 and histology, and a manageable safety profile in stage III NSCLC [54].